Dizal to Unveil Significant NSCLC Breakthroughs at ASCO 2026 Conference
Significant NSCLC Breakthroughs by Dizal at ASCO 2026
Dizal, a pioneering biopharmaceutical firm focused on developing innovative medicines for cancer and immunological disorders, has disclosed notable advancements in its non-small cell lung cancer (NSCLC) portfolio. The organization will present its latest findings at the prestigious American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled to take place in Chicago from May 29 to June 2, 2026. This announcement marks a crucial milestone for Dizal as it aims to improve treatment options for patients dealing with NSCLC.
The presentations will showcase clinical data on several of Dizal's investigational assets, including ZEGFROVY® (sunvozertinib), DZD6008, and golidocitinib. Among the highlights, the results from the significant Phase 3 WU-KONG28 study of ZEGFROVY have been selected for an oral presentation categorized as a Late-Breaking Abstract (LBA). This study focuses on ZEGFROVY, an oral, irreversible and highly selective EGFR tyrosine kinase inhibitor (TKI) designed to treat relapsed or refractory NSCLC patients harboring EGFR exon20ins mutations.
The WU-KONG28 study was a pivotal Phase 3 trial that compared the efficacy of sunvozertinib against a chemotherapy doublet in patients with newly diagnosed NSCLC who have the EGFR exon20ins mutation. Earlier updates revealed that the study achieved its primary endpoint, demonstrating a statistically significant and clinically meaningful enhancement in progression-free survival (PFS), which is crucial for patient outcomes.
In addition to ZEGFROVY, updated clinical findings regarding DZD6008 will also be presented. DZD6008 represents a novel, fourth-generation EGFR TKI with the unique capability to penetrate the blood-brain barrier. It is primarily aimed at advanced EGFR mutation-positive NSCLC patients who have previously succumbed to third-generation EGFR TKIs. This molecule has exhibited potent inhibitory effects across a wide range of EGFR mutations in preclinical models, suggesting its utility in managing treatment-resistant cases.
The presentation will further include insights from a study evaluating golidocitinib, which is notable as the first and only JAK1 inhibitor approved for treating relapsed or refractory peripheral T-cell lymphoma. Early findings are promising, indicating that JAK inhibition may help reinvigorate exhausted T-cell activity and alter the tumor microenvironment, thereby potentially enhancing the effectiveness of anti-PD-1/PD-L1 therapies for NSCLC patients who have previously been treated with these agents.
Dr. Xiaolin Zhang, the CEO of Dizal, expressed enthusiasm about the upcoming presentations, stating, "The data reported at ASCO 2026 reflect significant advancements in our NSCLC pipeline. We are particularly thrilled to share that WU-KONG28 has successfully met its primary endpoint. Targeting EGFR exon20ins has proven to be a challenging task, causing several compounds to fail in clinical trials. This positive outcome not only underlines ZEGFROVY's potential as an optimal treatment option for newly diagnosed lung cancer patients with EGFR exon20ins but also enhances our confidence in our development strategies."
Presentation Details
As part of the ASCO 2026 agenda, Dizal will feature the following research presentations:
- - Lead Author: Prof. John Heymach
Venue: Oral Abstract Session, Publication Number LBA8500
Time: May 29, 2026, 1:00 PM - 4:00 PM CDT
- - Lead Author: Prof. Mengzhao Wang
Venue: Rapid Oral Abstract Session, Publication Number 8520
Time: May 30, 2026, 1:15 PM - 2:45 PM CDT
- - Lead Author: Prof. Jie Wang
Venue: Poster Session, Publication Number 8555
Time: May 31, 2026, 9:00 AM - 12:00 PM CDT
With these presentations, Dizal underscores its commitment to addressing crucial medical needs within the oncology landscape, focusing on innovative and effective therapeutic solutions for patients with NSCLC. As the biopharmaceutical company continues its pursuit of groundbreaking treatments, the forthcoming ASCO conference provides a vital platform for sharing research that may redefine patient care in the realm of lung cancer treatment.
About Dizal
Dizal is a biopharmaceutical company dedicated to creating differentiated therapeutic agents for cancer and immunological diseases. Aiming to introduce first-in-class medicines and address unmet clinical needs globally, Dizal boasts an innovative portfolio enriched by multiple assets in pivotal global studies. Its leading products, ZEGFROVY and golidocitinib, have gained approvals in both the U.S. and China, showcasing the company’s impactful contributions to global health.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.